Novo Nordisk A/S (NVO)

NASDAQ

$50.38

+$0.21 (0.42%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$49.55$50.66

Open $49.96

52 Week Range

$43.08$109.88

Previous Close $50.17

Market Cap223.96B

Volume10.50M

Avg Volume16.78M

P/E (TTM)12.67

EPS (TTM)$24.98

Dividend / Yield$1.23 (2.44%)

Dividend StreakN/A

Latest Press Releases for Novo Nordisk A/S

DEC122025

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

Source: GlobeNewsWire•4 days ago

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)...

NOV252025

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes

Source: GlobeNewsWire•21 days ago

Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. This marks the first evaluation of amycretin in people with type 2 diabetes, fur...

NOV242025

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

Source: GlobeNewsWire•22 days ago

Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The two trials were randomised, double-blinded...

NOV192025

Novo Resources Releases 2025 Sustainability Report Highlighting Commitment to Integrity, People and the Environment

Source: GlobeNewsWire•27 days ago

PERTH, Western Australia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the publication of its 2025 Sustainability Report, detailing the Company's ongoing comm...

NOV172025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Source: GlobeNewsWire•29 days ago

Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation N...

NOV132025

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election

Source: GlobeNewsWire•32 days ago

Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November...

NOV112025

Novo Resources Announces Updated Investor Presentation

Source: GlobeNewsWire•34 days ago

PERTH, Australia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce that it has released an updated corporate presentation for investors....

NOV82025

Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

Source: GlobeNewsWire•38 days ago

Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Me...

NOV72025

Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE

Source: GlobeNewsWire•39 days ago

Fangzhou was named an “Outstanding Strategic Health Ecosystem Partner,” recognizing its role in advancing digital innovation in chronic disease management....

NOV62025

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

Source: PRNewsWire•39 days ago

A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to reduce or stop their medication1 CagriSema treatme...